[1] Tarrani, A.A. and Bailey, C.J. (2011) Management of Type 2 Diabetes: New and Future Developments in Treatment. Lancet, 378, 182-197. http://dx.doi.org/10.1016/S0140-6736(11)60207-9
[2] Arai, K., Matoba, K., Hirao, K., Matsuba, I., Takai, M., Takeda, H., Kanamori, A., Yamauchi, M., Mori, H. and Terauchi, Y. (2010) Present Status of Sulfonylurea Treatment for Type 2 Diabetes in Japan: Second Report of a Cross-Sectional Survey of 15,652 Patients. Endocrine Journal, 57, 499-507.
http://dx.doi.org/10.1507/endocrj.K09E-366
[3] Onuma, H., Inukai, K., Watanabe, M., Sumitani, Y., Hosaka, T. and Ishida, H. (2014) Effects of Long-Term Monotherapy with Glimepiride vs Glibenclamide on Glycemic Control and Macrovascular Events in Japanese Type 2 Diabetic Patients. Journal of Diabetes Mellitus, 4, 33-37.
http://dx.doi.org/10.4236/jdm.2014.41006
[4] Schweizer, A., Dejager, S., Foley, J.E. and Kothny, W. (2011) Assessing the General Safety and Tolerability of Vildagliptin: Value of Pooled Analyses from a Large Safety Database versus Evaluation of Individual Studies. Vascular Health and Risk Management, 7, 49-57. http://dx.doi.org/10.2147/VHRM.S16925
[5] Pratley, R.E. (2009) Alogliptin: A New, Highly Selective Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes. Expert Opinion on Pharmacotherapy, 10, 503-512.
http://dx.doi.org/10.1517/14656560802694713
[6] Araki, E., Kawamori, R., Inagaki, N., Watada, H., Hayashi, N., Horie, Y., Sarashina, A., Thiemann, S., Eynatten, M., Dugi, K. and Woerle, H.J. (2011) Long-Term Safety of Linagliptin Monotherapy in Japanese Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 13, 542-550.
[7] Eto, T., Inoue, S. and Kadowaki, T. (2012) Effects of Once-Daily Teneligliptin on 24-h Blood Glucose Control and Safety in Japanese Patients with Type 2 Diabetes Mellitus: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes, Obesity and Metabolism, 14, 1040-1046.
http://dx.doi.org/10.1111/j.1463-1326.2012.01662.x
[8] Ervinna, N., Mita, T., Yasunari, E., Azuma, K., Tanaka, R., Fujimura, S., Sukmawati, D., Nomiyama, T., Kanazawa, A., Kawamori, R., Fujitani, Y. and Watada, H. (2013) Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male Apo E-Deficient Mice. Endocrinology, 154, 1260-1270.
http://dx.doi.org/10.1210/en.2012-1855
[9] Gerrald, K.R., Van Scoyoc, E., Wines, R.C., Runge, T. and Jonas, D.E. (2012) Saxagliptin and Sitagliptin in Adult Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism, 14, 481-492. http://dx.doi.org/10.1111/j.1463-1326.2011.01540.x
[10] Williams-Herman, D., Engel, S.S., Round, E., Johnson, J., Golm, G.T., Guo, H., Musser, B.J., Davies, M.J., Kaufman, K.D. and Goldstein, B.J. (2010) Safety and Tolerability of Sitagliptin in Clinical Studies: A Pooled Analysis of Data from 10,246 Patients with Type 2 Diabetes. BMC Endocrine Disorders, 10, 7. http://dx.doi.org/10.1186/1472-6823-10-7
[11] Iwamoto, Y., Taniguchi, T., Nonaka, K., Okamoto, T., Okuyama, K., Arjona Ferreira, J.C. and Amatruda, J. (2010) Dose-Ranging Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus. Endocrine Journal, 57, 383-394. http://dx.doi.org/10.1186/1472-6823-10-7
[12] Park, H., Park, C., Kim, Y. and Rascati, K.L. (2012) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis. Annals of Pharmacotherapy, 46, 1453-1469.
http://dx.doi.org/10.1345/aph.1R041
[13] Lee, S., Yabe, D., Nohtomi, K., Takada, M., Morita, R., Seino, Y. and Hirano, T. (2010) Intact Glucagon-Like Peptide-1 Levels Are Not Decreased in Japanese Patients with Type 2 Diabetes. Endocrine Journal, 57, 119-126. http://dx.doi.org/10.1507/endocrj.K09E-269
[14] Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., Eckardt, K., Kaufman, J.M., Ryden, M., Müller, S., Hanisch, F.G., Ruige, J., Arner, P., Sell, H. and Eckel, J. (2011) Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. Diabetes, 60, 1917-1925. http://dx.doi.org/10.2337/db10-1707
[15] Kang, Z.F., Deng, Y., Zhou, Y., Fan, R.R., Chan, J.C., Laybutt, D.R., Luzuriaga, J. and Xu, G. (2013) Pharmacological Reduction of NEFA Restores the Efficacy of Incretin-Based Therapies through GLP-1 Receptor Signalling in the Beta Cell in Mouse Models of Diabetes. Diabetologia, 56, 423-433.
http://dx.doi.org/10.1007/s00125-012-2776-x
[16] Ranganath, L.R., Beety, J.M. and Morgan, L.M. (1996) Attenuated GLP-1 Secretion in Obesity: Cause or Consequence? Gut, 38, 916-919. http://dx.doi.org/10.1136/gut.38.6.916
[17] Yusta, B., Baggio, L.L., Estall, J.L., Koehler, J.A., Holland, D.P., Li, H., Pipeleers, D., Ling, Z. and Drucker, D.J. (2006) GLP-1 Receptor Activation Improves Beta Cell Function and survival Following Induction of Endoplasmic Reticulum Stress. Cell Metabolism, 4, 391-406.
http://dx.doi.org/10.1016/j.cmet.2006.10.001
[18] Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D. and Khatami, H. (2006) Sitagliptin Study 023 Group, Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy in Patients with type 2 Diabetes Mellitus. Diabetologia, 49, 2564-2571.
http://dx.doi.org/10.1007/s00125-006-0416-z
[19] F-Wind and Chikushi-JRN Group (2012) Contributing Factors Related to Efficacy of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in Japanese Patients with Type 2 Diabetes. Diabetes Research and Clinical Practice, 95, e27-e28. http://dx.doi.org/10.1016/j.diabres.2011.08.016
[20] Maeda, H., Kubota, A., Tanaka, Y., Terauchi, Y. and Matsuba, I. (2012) The Safety, Efficacy and Predictors for HbA1c Reduction of Sitagliptin in the Treatment of Japanese Type 2 Didbetes. Diabetes Research and Clinical Practice, 95, e20-e22. http://dx.doi.org/10.1016/j.diabres.2011.10.011
[21] Bando, Y., Kanehara, H., Aoki, K., Hisada, A., Toya, D. and Nobuyoshi, T. (2012) Obesity May Attenuate the HbA1c-Lowering Effect of Sitagliptin in Japanese Type 2 Diabetic Patients. Journal of Diabetes Investigation, 3, 170-174. http://dx.doi.org/10.1111/j.2040-1124.2011.00156.x
[22] Solis-Herrera, C., Triplitt, C., Garduno-Garcia, J.J., Adams, J., Defronzo, R.A. and Cersosimo, E. (2013) Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or with Metformin in Type 2 Diabetes: A Double-Tracer Study. Diabetes Care, 36, 2756-2762.
http://dx.doi.org/10.2337/dc12-2072
[23] Green, B.D., Irwin, N., Duffy, N.A., Gault, V.A., O’Harte, F.P. and Flatt, P.R. (2006) Inhibition of Dipeptidyl Peptidase-IV Activity by Metformin Enhances the Antidiabetic Effects of Glucagon-Like Peptide-1. European Journal of Pharmacology, 547, 192-199.
http://dx.doi.org/10.1016/j.ejphar.2006.07.043
[24] Aoki, K., Masuda, K., Miyazaki, T., Togashi, Y. and Terauchi, Y. (2010) Effects of Miglitol, Sitagliptin or Their Combination on Plasma Glucose, Insulin and Incretin Levels in Non-Diabetic Men. Endocrine Journal, 57, 667-672. http://dx.doi.org/10.1507/endocrj.K10E-103